CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 468 enrolled
Drug / intervention
Loratadine (Claritin, BAY76-2211)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04162795
NCT04162795Phase 4Completed
CompareCT.gov

An Open Label, Multi-center Study to Evaluate Sensory Attributes of an Antihistamine Product

Bayer·interventional·Posted Nov 14, 2019·Updated Feb 4, 2021

In Brief

A Phase 4 clinical trial evaluating Loratadine (Claritin, BAY76-2211) for Allergic Rhinitis. Completed, enrolled 468 participants across 1 site.

Detailed Summary

In this study, researchers were primarily interested in evaluating the level of agreement of cooling sensation provided by this chewable, flavored, allergy medicine. Participants joining this study received one test drug tablet and were asked to chew completely before swallowing the drug. A questionnaire was used to collect the feedback from participants. The study involved only one (1) visit and participant stayed in this study for about 60-75 minutes to evaluate the cooling sensation as well as other sensory attributes perceived in the mouth, nose and throat.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Rhinitis
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2020202120222023202420252026
First PostedNov 14, 2019
Enrollment StartNov 12, 2019
Primary CompletionNov 13, 2019
TodayJul 2, 2026
Enrollment to primary: 1 daysPosted 6.6 years ago

Interventions

Loratadine (Claritin, BAY76-2211)drug

Chewable tablet, oral, single dose